Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …

It is well recognised that the majority of the impact of multiple sclerosis (MS), both personal
and societal, arises in the progressive phase where disability accumulates inexorably. As …

The predominant clinical disease course of multiple sclerosis (MS) which can be treated
today by a variety of different disease-modifying treatments (DMT) is characterized by …

New MS treatments may provide the basis for aggressive early intervention in patients with
MS and intensification of treatment when disease is not controlled. The availability of …

Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting
disease, many transition to secondary progressive disease (SPMS) over time. This transition …

Background: Since the commercial introduction of disease-modifying drugs (DMDs) for the
treatment of multiple sclerosis (MS), there have been numerous randomized placebo …

The treatment algorithm for RRMS is becoming increasingly complex with the ever-
expanding armamentarium of DMTs. The choice of DMT will become an increasingly …

Secondary progressive multiple sclerosis (SPMS) is characterized by progressive
accumulation of disability without intermittent recovery. Treatment of these patients is …

Importance A number of officially approved disease-modifying drugs (DMD) are currently
available for the early intervention in patients with relapsing-remitting multiple sclerosis …

Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing
multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) …